Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other financing activities (2021 - 2025)

Cytek Biosciences' Other financing activities history spans 5 years, with the latest figure at $268000.0 for Q4 2025.

  • For Q4 2025, Other financing activities rose 106.15% year-over-year to $268000.0; the TTM value through Dec 2025 reached $670000.0, up 20.94%, while the annual FY2025 figure was $670000.0, 20.94% up from the prior year.
  • Other financing activities reached $268000.0 in Q4 2025 per CTKB's latest filing, up from $171000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $268000.0 in Q4 2025 to a low of -$1.1 million in Q3 2021.
  • Average Other financing activities over 5 years is $48187.5, with a median of $120000.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: soared 159.65% in 2024, then decreased 21.54% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$1.1 million in 2021, then soared by 106.57% to $71000.0 in 2022, then skyrocketed by 43.66% to $102000.0 in 2023, then grew by 27.45% to $130000.0 in 2024, then surged by 106.15% to $268000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Other financing activities are $268000.0 (Q4 2025), $171000.0 (Q3 2025), and $102000.0 (Q2 2025).